Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 4
Submit an article Journal homepage
232
Views
11
CrossRef citations to date
0
Altmetric
Theme: Lung Cancer - Review

Zoledronic acid in lung cancer with bone metastases: a review

Dolores Isla Servicio de Oncología Médica, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [email protected]; Servicio de Oncología Médica, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [email protected]
,
Ruth Afonso Servicio de Oncología Médica, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain; Servicio de Oncología Médica, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
,
Joaquim Bosch-Barrera Servicio de Oncología Médica, Instituto Catalán de Oncología, Hospital Doctor Josep Trueta, Girona, Spain; Servicio de Oncología Médica, Instituto Catalán de Oncología, Hospital Doctor Josep Trueta, Girona, Spain
&
Natividad Martínez Servicio de Oncología Médica, Hospital General Universitario de Elche, Alicante, Spain; Servicio de Oncología Médica, Hospital General Universitario de Elche, Alicante, Spain
Pages 421-426 | Published online: 10 Jan 2014

References

  • Brodowicz T, O’Byrne K, Manegold C. Bone matters in lung cancer. Ann. Oncol. 23(9), 2215–2222 (2012).
  • Coleman RE. Metastatic bone disease and the role of biochemical markers of bone metabolism in benign and malignant diseases. Cancer Treat. Rev. 27(3), 133–135 (2001).
  • Roodman GD. Biology of osteoclast activation in cancer. J. Clin. Oncol. 19(15), 3562–3571 (2001).
  • Brown JE, Cook RJ, Major P et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl Cancer Inst. 97(1), 59–69 (2005).
  • Huang Q, Ouyang X. Biochemical-markers for the diagnosis of bone metastasis: a clinical review. Cancer Epidemiol. 36(1), 94–98 (2012).
  • Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol. 16(4), 579–584 (2005).
  • Coleman RE. Skeletal complications of malignancy. Cancer 80(Suppl. 8), 1588–1594 (1997).
  • Decoster L, de Marinis F, Syrigos K, Hirsh V, Nackaerts K. Bisphosphonates: prevention of bone metastases in lung cancer. Recent Results Cancer Res. 192, 93–108 (2012).
  • Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27(3), 165–176 (2001).
  • Hamdy NA. Denosumab: RANKL inhibition in the management of bone loss. Drugs Today 44(1), 7–21 (2008).
  • George S, Brenner A, Sarantopoulos J, Bukowski RM. RANK ligand: effects of inhibition. Curr. Oncol. Rep. 12(2), 80–86 (2010).
  • Russell RG. Bisphosphonates: the first 40 years. Bone 49(1), 2–19 (2011).
  • Conte P, Coleman R. Bisphosphonates in the treatment of skeletal metastases. Semin. Oncol. 31(5 Suppl. 10), 59–63 (2004).
  • Ricciardi S, de Marinis F. Treatment of bone metastases in lung cancer: the actual role of zoledronic acid. Rev. Recent Clin. Trials 4(3), 205–211 (2009).
  • Langer C, Hirsh V. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer 67(1), 4–11 (2010).
  • Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21(16), 3150–3157 (2003).
  • Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100(12), 2613–2621 (2004).
  • Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 113(6), 1438–1445 (2008).
  • Delea TE, McKiernan J, Brandman J et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J. Thorac. Oncol. 1(6), 571–576 (2006).
  • Joshi AD, Carter JA, Botteman MF, Kaura S. Cost–effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom. Clin. Ther. 33(3), 291–304.e8 (2011).
  • Piga A, Bracci R, Ferretti B et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J. Exp. Clin. Cancer Res. 17(2), 213–217 (1998).
  • Francini F, Pascucci A, Bargagli G et al. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. Int. J. Clin. Oncol. 16(3), 264–269 (2011).
  • Bosch-Barrera J, Merajver SD, Menéndez JA, Van Poznak C. Direct antitumour activity of zoledronic acid: preclinical and clinical data. Clin. Transl. Oncol. 13(3), 148–155 (2011).
  • Hirsh V, Major PP, Lipton A et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J. Thorac. Oncol. 3(3), 228–236 (2008).
  • Zarogoulidis K, Boutsikou E, Zarogoulidis P et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int. J. Cancer 125(7), 1705–1709 (2009).
  • Calderone R, Nimako K, Leary A, Popat S, O’Brien ME. Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease – a short communication. Eur. J. Cancer 47(11), 1603–1605 (2011).
  • Pandya KJ, Gajra A, Warsi GM, Argonza-Aviles E, Ericson SG, Wozniak AJ. Multicenter, randomized, Phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer 67(3), 330–338 (2010).
  • Scagliotti GV, Kosmidis P, de Marinis F et al. Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, Phase III study. Ann. Oncol. 23(8), 2082–2087 (2012).
  • Mahtani R, Khan R, Jahanzeb M. The potential application of zoledronic acid as anticancer therapy in patients with non-small cell lung cancer. Clin. Lung Cancer 12(1), 26–32 (2011).
  • Coleman R, Cook R, Hirsh V, Major P, Lipton A. Zoledronic acid use in cancer patients: more than just supportive care? Cancer 117(1), 11–23 (2011).
  • Dhillon S, Lyseng-Williamson KA. Zoledronic acid: a review of its use in the management of bone metastases of malignancy. Drugs 68(4), 507–534 (2008).
  • De Marinis F, Eberhardt W, Harper PG et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J. Thorac. Oncol. 4(10), 1280–1288 (2009).
  • Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res. 23(6), 826–836 (2008).
  • Aapro M, Abrahamsson PA, Body JJ et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann. Oncol. 19(3), 420–432 (2008).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.